An open-label, two-treatment, two-sequence, two-period, balanced, randomized, single dose, cross over, comparative bioavailability study of ZYO1 tablet [20mg tablet and 5mg tablet - old (first) formulation] of M/S Cadila Healthcare Ltd., Ahmedabad, India with ZYO1 tablet [20 mg tablet and 5 mg tablet - new (second) formulation] of M/S Cadila Healthcare Ltd., Ahmedabad, India in healthy, adult, male, human subjects under fasting conditions.

Trial Profile

An open-label, two-treatment, two-sequence, two-period, balanced, randomized, single dose, cross over, comparative bioavailability study of ZYO1 tablet [20mg tablet and 5mg tablet - old (first) formulation] of M/S Cadila Healthcare Ltd., Ahmedabad, India with ZYO1 tablet [20 mg tablet and 5 mg tablet - new (second) formulation] of M/S Cadila Healthcare Ltd., Ahmedabad, India in healthy, adult, male, human subjects under fasting conditions.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs ZY 01 (Primary)
  • Indications Obesity
  • Focus Pharmacokinetics
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 23 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top